BPC-157 vs TB-500: Differences, Evidence and Side Effects
BPC-157 vs TB-500 comes down to two different peptides with two different study records. BPC-157 is a short peptide tested mostly in the gut and tendons. TB-500 is a fragment of a body protein tested mostly in the heart, vessels and skin. Almost all of the healing results are from animals, and neither peptide is approved.
The quick contrast
- BPC-157: a 15 amino acid peptide from stomach juice; three tiny human pilot studies exist.
- TB-500: a lab fragment of thymosin beta-4, a 43 amino acid protein; human trials exist only for the parent protein in skin ulcers.
- Both: mostly animal evidence, no approval, and a shared theoretical concern about new blood vessel growth.
This page sets the two peptides side by side and ties each claim to a study you can open. None of the top results we read on 23 October 2026 did that; one review page even states that no specific doses have been studied. Below, every row names the model, the route and the paper behind it.
Sources: McGuire with colleagues, 2025 in Curr Rev Musculoskelet Med, a review that counts just three human pilot studies so far. PMID 40789979; Sikiric P with colleagues, 2011 in Curr Pharm Des, a rat and lab survey of this gut-protective peptide that found no toxicity in its models. PMID 21548867; Goldstein with colleagues, 2012 in Expert Opin Biol Ther, a review of thymosin beta 4, the protein that TB-500 is cut from. PMID 22074294
BPC-157 or TB-500: which is better?
No study has ever put them head to head in people for a fair winner. They are studied for different jobs. BPC-157 shows up most in gut and tendon animal work. TB-500, through its parent protein, shows up most in heart and skin work. Picking one is not a science question yet, because the human proof needed to compare them does not exist.
What follows is a report of the research record, not advice to use either one. Both are sold as research chemicals, and no medicines agency lists them for healing.
Sources: McGuire with colleagues, 2025 in Curr Rev Musculoskelet Med, a review that counts just three human pilot studies so far. PMID 40789979; Sikiric P with colleagues, 2011 in Curr Pharm Des, a rat and lab survey of this gut-protective peptide that found no toxicity in its models. PMID 21548867
What is BPC-157, and what is TB-500?
BPC-157 is a made-up chain of 15 amino acids. It copies a piece of a protective compound found in human stomach juice, and it stays stable in stomach acid. Lab papers describe it acting on the VEGF blood vessel pathway and the nitric oxide system.
TB-500 is not the same as its famous parent. It is a short synthetic piece of thymosin beta-4, a natural 43 amino acid protein that helps cells move and heal. A lot of what is sold online as TB-500 research is really data on that full protein. The two are related but not identical, which matters when you read the evidence.
For the single compounds, our BPC-157 profile and TB-500 profile cover each one on its own.
Sources: Sikiric P with colleagues, 2011 in Curr Pharm Des, a rat and lab survey of this gut-protective peptide that found no toxicity in its models. PMID 21548867; Seiwerth S with colleagues, 2018 in Curr Pharm Des, which set the peptide against VEGF and other vessel-growth signals in animal repair. PMID 29998800; Goldstein with colleagues, 2012 in Expert Opin Biol Ther, a review of thymosin beta 4, the protein that TB-500 is cut from. PMID 22074294; Philp with colleagues, 2003 in FASEB J, on the actin-grabbing region of thymosin beta 4 and new vessel growth. PMID 14500546
What was each peptide actually tested in?
Here is the part the other guides skip. This table names the kind of study, the route, and whether any work was done in people, with the study numbers so you can check each line yourself.
| Peptide | Size | Main study models | Routes studied | Any human studies? | Study IDs (PMID) |
|---|---|---|---|---|---|
| BPC-157 | 15 amino acids | Rat and cell studies: stomach and gut, brain, Achilles tendon | Oral, under the skin, into the joint | Yes, but only 3 small pilots: knee pain, bladder pain, and a 2 person safety test | 21548867, 34380875, 21030672, 34324435, 39325560, 40131143 |
| TB-500 (thymosin beta-4) | A short fragment; its parent protein is 43 aa | Rat and cell studies: heart, blood vessels, skin wounds | Under the skin and into muscle in animal work | Thymosin beta-4 itself reached 2 phase 2 skin-ulcer trials; TB-500 for sport has none | 14500546, 23045975, 23050815, 22074294 |
The three BPC-157 human pilots were small and uncontrolled. The amounts on record were:
Knee pain: a chart review, with the amount not stated
Bladder pain: a single dose placed into the bladder of 10 mg
Safety drip: 10 mg then 20 mg given by vein in 2 adults
Disclaimer: these are the amounts used inside small studies, shown here to describe the research. They are not a dose to copy, and BPC-157 has no approved dose.
Sources: Lee and Padgett, 2021 in Altern Ther Health Med, a look back at 16 knee-pain patients treated at one clinic, with no control group. PMID 34324435; Lee with colleagues, 2024 in Altern Ther Health Med, a pilot in 12 women with bladder pain, a single clinic dose, no control group. PMID 39325560; Lee and Burgess, 2025 in Altern Ther Health Med, a drip safety check in 2 adults given the peptide by vein. PMID 40131143; Philp with colleagues, 2003 in FASEB J, on the actin-grabbing region of thymosin beta 4 and new vessel growth. PMID 14500546; Gupta with colleagues, 2012 in Ann N Y Acad Sci, on thymosin beta 4 in an animal heart-attack model. PMID 23045975; Treadwell with colleagues, 2012 in Ann N Y Acad Sci, covering animal wounds plus two phase 2 skin-ulcer trials in patients. PMID 23050815
How does each peptide work in studies?
The proposed routes differ. In lab models, BPC-157 switches on the VEGF blood vessel pathway, works through nitric oxide, and shifts growth factors tied to repair. Papers also report effects on the brain, the gut lining and tendon cells.
TB-500 is built around a short part of thymosin beta-4 that grabs actin, a building block inside cells. That action is linked to cell movement and new vessel growth. Animal papers add heart protection after a simulated heart attack and faster skin wound closure.
Both pathways push new blood vessels. That is why every careful review raises the same caution: anything that grows vessels could, in theory, feed a tumour. No study has shown this happens with either peptide, and none has ruled it out.
Sources: Seiwerth S with colleagues, 2018 in Curr Pharm Des, which set the peptide against VEGF and other vessel-growth signals in animal repair. PMID 29998800; Vukojevic J with colleagues, 2022 in Neural Regen Res, a round-up of rat brain studies. PMID 34380875; Chang CH with colleagues, 2011 in J Appl Physiol, testing the peptide on rat Achilles tendon and on tendon cells in a dish. PMID 21030672; Philp with colleagues, 2003 in FASEB J, on the actin-grabbing region of thymosin beta 4 and new vessel growth. PMID 14500546; Gupta with colleagues, 2012 in Ann N Y Acad Sci, on thymosin beta 4 in an animal heart-attack model. PMID 23045975; McGuire with colleagues, 2025 in Curr Rev Musculoskelet Med, a review that counts just three human pilot studies so far. PMID 40789979
Which one has real human evidence?
Both have a thin human record. A 2025 review of BPC-157 was blunt: human data are extremely limited, with only three pilot studies. None used a placebo group, and all were tiny.
TB-500 is sold for injury recovery, yet no human trial tested it for that on its own. The closest is a small knee chart review of 17 patients, 16 of whom were reached for follow-up, in which 4 were given BPC-157 together with thymosin beta-4. The dedicated human trials belong to the parent protein, thymosin beta-4, in two phase 2 studies of leg and pressure ulcers. Those reported faster healing in some patients, for a skin use, not a sports use.
So neither peptide has the large, controlled trials that back an approved drug. For how peptides move from a lab to a clinic, see our HGH vs peptides guide.
Sources: McGuire with colleagues, 2025 in Curr Rev Musculoskelet Med, a review that counts just three human pilot studies so far. PMID 40789979; Lee and Padgett, 2021 in Altern Ther Health Med, a look back at 16 knee-pain patients treated at one clinic, with no control group. PMID 34324435; Lee with colleagues, 2024 in Altern Ther Health Med, a pilot in 12 women with bladder pain, a single clinic dose, no control group. PMID 39325560; Lee and Burgess, 2025 in Altern Ther Health Med, a drip safety check in 2 adults given the peptide by vein. PMID 40131143; Treadwell with colleagues, 2012 in Ann N Y Acad Sci, covering animal wounds plus two phase 2 skin-ulcer trials in patients. PMID 23050815
What side effects were reported?
In the studies on record, the clearest effect is a mild reaction at the injection spot. The small human BPC-157 work reported few problems: the 2 person drip test found no change in heart, liver, kidney or blood sugar markers, and the bladder study reported no adverse events.
- Short, small studies cannot catch rare or slow harms, so a clean small trial is not a safety guarantee.
- The vessel growth both peptides trigger is a theoretical cancer concern that reviewers keep flagging.
- Research-grade vials vary in purity and dose, which adds its own risk on top of the peptide itself.
If you are weighing purity and testing, our guide to certificates of analysis explains what a published lab report should show.
Sources: Lee and Burgess, 2025 in Altern Ther Health Med, a drip safety check in 2 adults given the peptide by vein. PMID 40131143; Lee with colleagues, 2024 in Altern Ther Health Med, a pilot in 12 women with bladder pain, a single clinic dose, no control group. PMID 39325560; Lee and Padgett, 2021 in Altern Ther Health Med, a look back at 16 knee-pain patients treated at one clinic, with no control group. PMID 34324435; McGuire with colleagues, 2025 in Curr Rev Musculoskelet Med, a review that counts just three human pilot studies so far. PMID 40789979
Are BPC-157 and TB-500 approved?
No. Neither is an approved medicine, and neither is a legal supplement ingredient. Both are sold as research chemicals, which carries no promise of safety, purity or benefit. In sport, growth and repair peptides like these sit on the banned list for tested athletes.
For the stack people often ask about, see the Wolverine stack guide, and for mixing math there is the BPC-157 and TB-500 blend calculator. This page stays on the head to head and leaves blend math to those tools.
Disclosure: Some links on this page are referral links. Peptides Vietnam may earn a fee at no cost to you. Editorial content is never sold.
Looking for research vials locally? You can check with Peptara Labs about which peptides they currently carry in Vietnam. A research listing is not a medicine, and nothing on it turns these study figures into a dose for you.
Common questions
What is the difference between BPC-157 and TB-500?+
BPC-157 is a 15 amino acid peptide copied from a protein in stomach juice. TB-500 is a shorter synthetic version of thymosin beta-4, a 43 amino acid protein in the body. Their study records differ too. Most BPC-157 work targets the gut and tendons. Most TB-500 work targets the heart, blood vessels and skin.
Do BPC-157 peptides actually work?+
Most of the healing results come from rats and cell dishes, not people. A 2025 review found only three small human pilot studies of BPC-157, none with a control group. So the honest answer is that strong human proof is missing, and no health agency has approved it.
How often should you inject TB-500?+
No human trial has set a schedule for TB-500 as a healing injection. The dosing charts sold online are not based on a published human study. This page reports what the research tested, not a plan to follow. A licensed clinician is the one who would set any schedule, never a web chart.
What are the side effects of BPC-157 and TB-500 injections?+
The most common reported effect in studies is a mild reaction where the needle goes in. In a 2 person BPC-157 drip test, blood markers for the heart, liver, kidneys and blood sugar did not change. The bigger open question is the long term: both peptides can promote new blood vessel growth, which reviewers flag as a theoretical cancer concern. Long term human safety is simply unstudied.
Is TB-500 safe?+
There is no long term human safety trial for TB-500 used for injury recovery. The parent protein, thymosin beta-4, was tested in two phase 2 trials for skin ulcers, but that is a different use and a different product. Neither TB-500 nor BPC-157 is approved anywhere for healing injuries.
Which one has human data?+
Both have a little, and neither has much. BPC-157 has three tiny pilot studies in people. Thymosin beta-4, the protein behind TB-500, reached two phase 2 skin-ulcer trials. Neither peptide has a large controlled trial for the muscle and tendon uses they are sold for.
Sources: McGuire with colleagues, 2025 in Curr Rev Musculoskelet Med, a review that counts just three human pilot studies so far. PMID 40789979; Lee and Burgess, 2025 in Altern Ther Health Med, a drip safety check in 2 adults given the peptide by vein. PMID 40131143; Treadwell with colleagues, 2012 in Ann N Y Acad Sci, covering animal wounds plus two phase 2 skin-ulcer trials in patients. PMID 23050815
More on these peptides
BPC-157 Profile
Evidence, study doses and side effects
TB-500 Profile
What the thymosin beta-4 fragment is
Wolverine Stack
The BPC-157 and TB-500 combination
Blend Dosage Calculator
Mixing math for a combined vial
Peptide Reconstitution Calculator
Water, strength and syringe units
HGH vs Peptides
How repair peptides compare to HGH
This head to head from Peptides Vietnam sums up the published studies on BPC-157 and TB-500 and nothing more. Treat it as background, not as medical guidance; it sets no dose and backs no peptide. Neither compound is an approved medicine.